Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Women in the Broadmoor-Anderson Island-Shreve Isle area of Shreveport, Louisiana can access FDA-approved GLP-1 receptor agonist medications through our female-focused telehealth consultations. Our network of LA-licensed physicians helps women in Caddo County address the hormonal drivers of weight gain — including PCOS-related insulin resistance, menopausal metabolic changes, and estrogen-linked fat storage patterns.
GLP-1 medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are prescribed by female health-aware board-certified physicians who bring a hormone-sensitive approach to treatment. By consulting privately from home in Shreveport, women receive the thorough female health evaluation that in-person visits often rush.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
Ozempic (diabetes) and Wegovy (weight management). Weekly injection — STEP trials documented 14-15%% average weight loss for women specifically.
Mounjaro (diabetes) and Zepbound (weight loss). Dual-action GIP/GLP-1 — the strongest female weight loss outcomes available, ideal for menopausal metabolic resistance.
Landmark randomized controlled trials in the New England Journal of Medicine establish the efficacy profile of FDA-approved GLP-1 medications available to Broadmoor-Anderson Island-Shreve Isle, Shreveport residents:
Telehealth prescribing of GLP-1 receptor agonists in Louisiana is conducted by board-certified, LA-licensed physicians through HIPAA-compliant platforms. GLP-1 medications are not DEA-scheduled controlled substances and may be prescribed via telehealth after a valid clinical evaluation.
Accessing female-responsive GLP-1 medication from Broadmoor-Anderson Island-Shreve Isle is entirely online and built around the female health experience. Physicians take your hormonal history seriously — not just your weight numbers — and build your treatment accordingly.
Complete a brief female-focused health questionnaire from your home in Broadmoor-Anderson Island-Shreve Isle. Covers your medical history, hormonal background, PCOS status, menstrual and menopausal history, current medications, and weight goals — giving your physician the full female metabolic picture in just 5 minutes.
A LA-licensed physician experienced in female metabolic health reviews your health profile and conducts a private telehealth consultation. They recommend the most appropriate GLP-1 option for your hormonal situation — with dosing guidance designed for female-responsive care.
Once prescribed, your GLP-1 medication ships from a licensed US pharmacy directly to your Broadmoor-Anderson Island-Shreve Isle address. Most women in Shreveport receive their medication within 3-5 business days, along with their personalized female-responsive treatment plan.
Our female-focused GLP-1 telehealth physicians serve all neighborhoods in Shreveport and surrounding areas with the same hormone-aware care.
Find female-focused GLP-1 telehealth services across every neighborhood in Shreveport, LA.
Also offering female-focused GLP-1 therapy in cities near Shreveport through our licensed women's health network.
Female-focused GLP-1 telehealth services available in the largest cities across Louisiana.
Our female-focused GLP-1 telehealth network brings hormone-aware care to women across the largest cities in the United States.
Local weight loss and GLP-1 providers serving the Broadmoor-Anderson Island-Shreve Isle, Shreveport area, based on Google Business listings.
1953 E 70th St, Shreveport, LA 71105
5/5 ★ (40 reviews)
6969 Fern Loop Suite 205B, Shreveport, LA 71105
4.4/5 ★ (7 reviews)
3532 Youree Dr Suite A
5/5 ★ (41 reviews)
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes. Women in Broadmoor-Anderson Island-Shreve Isle and throughout Shreveport, Louisiana can benefit significantly from GLP-1 therapy. Our LA-licensed physicians evaluate each woman's hormonal history — PCOS, menopause, postpartum status, estrogen levels — and prescribe a female-responsive GLP-1 plan designed to address the root drivers of female weight gain.
Yes. GLP-1 is considered highly beneficial for women with PCOS in Broadmoor-Anderson Island-Shreve Isle and throughout Shreveport because it directly addresses insulin resistance — the root metabolic driver of PCOS-related weight gain, hormonal imbalance, and irregular cycles. Many women experience significant improvement in both weight and hormonal markers.
Absolutely. Menopausal weight gain is driven by hormonal shifts that GLP-1 directly addresses. Women in Shreveport in perimenopause or full menopause find GLP-1 particularly effective because it counteracts the abdominal fat accumulation mechanism tied to declining estrogen. Our physicians account for menopausal status in prescribing.
For Caddo County women, our physicians evaluate individual hormonal profiles before prescribing. Available options include semaglutide (Ozempic, Wegovy) — with 14-15% average female weight loss data — and tirzepatide (Mounjaro, Zepbound) — delivering up to 22% average weight reduction. Liraglutide (Saxenda) is also available for daily dosing preference.
Telehealth allows for thorough, unhurried female health consultations that in-person visits often compress. Our LA-licensed physicians take a complete hormonal history, assess PCOS and menopause status, and monitor female-specific responses to GLP-1 throughout treatment. The private home environment also makes it easier for women to discuss sensitive hormonal health topics openly.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
